HKSE - Delayed Quote HKD

Jiangsu Hengrui Pharmaceuticals Co.,Ltd (1276.HK)

50.950 +0.250 (+0.49%)

As of 11:59:23 AM GMT+8. Market Open.

Chart Range Bar

Loading chart for 1276.HK

Previous Close 50.700
Open 50.700
Bid 50.850 x --
Ask 50.950 x --
Day's Range 49.960 - 51.200
52 Week Range 43.020 - 80.950
Volume 1,576,566
Avg. Volume 5,317,215
Market Cap (intraday) 338.165B
Beta (5Y Monthly) 0.05
PE Ratio (TTM) 33.52
EPS (TTM) 1.520
Earnings Date --
Forward Dividend & Yield 0.23 (0.45%)
Ex-Dividend Date Apr 29, 2026
1y Target Est 77.59

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.

www.hengrui.com

20,602

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Drug Manufacturers - Specialty & Generic

Industry

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

1276.HK

28.39%

SSE Composite Index (000001.SS)

8.26%

1-Year Return

1276.HK

32.01%

SSE Composite Index (000001.SS)

7.94%

3-Year Return

1276.HK

11.55%

SSE Composite Index (000001.SS)

20.99%

5-Year Return

1276.HK

11.55%

SSE Composite Index (000001.SS)

3.86%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q3 FY26

Revenue 8.95B

Earnings 2.46B

Profit Margin 27.45%

FY25

FY26

24.0%

26.0%

28.0%

Analyst Price Targets

55.22

77.59 Average

50.950 Current

121.30 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

27.04%
Return on Assets (ttm)

7.77%
Return on Equity (ttm)

13.94%
Revenue (ttm)

32.85B
Net Income Avi to Common (ttm)

8.88B
Diluted EPS (ttm)

1.520

Balance Sheet and Cash Flow

Total Cash (mrq)

38.84B
Total Debt/Equity (mrq)

0.10%
Levered Free Cash Flow (ttm)

1.55B

1801.HK

9926.HK

6160.HK

2359.HK

3692.HK

U.S. markets closed

Jiangsu Hengrui Pharmaceuticals Co.,Ltd (1276.HK)

8.08%

2.60%

-21.62%

-28.64%

-32.25%

-11.55%

-11.55%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd Overview Drug Manufacturers - Specialty & Generic / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch